WinstonWınston
Back
Coloplast A/S logo

Coloplast A/S

COLO-B.CO
64
Medical - Instruments & Supplies · Healthcare
Exchange
NASDAQ Copenhagen
Winston Score
64
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Strong
Growth
Weak
Cash Flow
Exceptional
Stability
Good
Valuation
Good
Dividends
Strong

Winston Score History

The full picture

Coloplast is a Danish medical device company that makes products for people with intimate health conditions — things like ostomy bags (for people who have had bowel surgery), catheters, wound care dressings, and continence products. Its customers are mostly patients, hospitals, and home care providers across the world. Coloplast is one of the largest companies in the world focused specifically on ostomy and continence care.

The company sells its products directly to healthcare systems and through distributors, earning revenue from ongoing product purchases rather than one-time sales — patients typically need these supplies every day for life. Coloplast operates in over 40 countries, with Europe as its largest market, though it has been growing in the United States and emerging markets. Its main competitive advantages are strong brand loyalty among patients and clinicians and deep specialization in a niche that larger medical device companies tend to ignore. The key growth risk is pricing pressure from healthcare systems looking to cut costs on consumable medical supplies.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.7% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+81.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

36.6%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

kr 962M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Coloplast A/S is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
66.7%
Premium pricing power — 66.7% gross margin
Profit after running costs
Operating Margin
25.9%
Excellent — 25.9% operating margin
Return on the money invested
ROCE
20.6%
Exceptional — 20.6% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+2.1%
Nearly flat sales (+2.1% YoY)
Profit growth
EPS YoY
-32.2%
Earnings shrinking (-32.2% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
278%
Turns 278% of profit into real cash
Spare cash per sale
FCF Margin
22.0%
Converts sales into free cash efficiently (22.0%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.73
Elevated debt (1.73)
Covers its interest
Interest Cover
10.75x
Comfortably covers interest (10.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
35.8x
no trend
Pricey — P/E 35.8

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
+20.7
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (35.8 → 15.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
5.31%
no trend
Healthy income — 5.31% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend record
Dividend Growth
+9.8%
no trend
Dividend growing modestly (9.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial